Search

everythinglearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.

ALRN-6924 may prevent hair loss caused by chemotherapy.

The rash resolved after stopping ponatinib.

Gefitinib therapy can cause unusual hair growth on the nose.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Trichodynia is a painful scalp condition linked to hair loss and inflammation, often with anxiety, affecting more women and needing better treatment options.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Upadacitinib effectively treats psoriasis and lichen planus together.

Many medications may be linked to cognitive disorders, but most lack warnings on labels.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Axitinib treatment turned a man's grey hair back to black.